Is the FTO rs9939609 A/A genotype linked to higher body mass and insulin resistance?

The association between the FTO rs9939609 A/A genotype and metabolic risk is supported by robust clinical and mechanistic evidence, highlighting a clear pathway from genetic predisposition to altered body composition and subsequent insulin resistance.

Body composition and genetic risk

Meta-analyses and longitudinal studies consistently identify the FTO rs9939609 A allele as a primary genetic risk factor for increased adiposity.

• Weight and BMI: Homozygous AA carriers typically weigh approximately 3 kg more than non-carriers. Research across various adult populations, including females, shows odds ratios for obesity ranging from 1.23 to 1.31 per risk allele.
• Adiposity distribution: The A allele is linked to a 2.5% increase in total body fat and a 0.7-unit elevation in visceral fat. This increase in visceral adipose tissue (VAT) is a hallmark of the central adiposity associated with this variant.

Mechanisms of insulin resistance

Central adiposity, particularly visceral fat expansion, promotes insulin resistance through two primary interconnected pathways involving hormonal suppression and inflammatory activation:

• Adiponectin suppression: VAT shows a specific decline in adiponectin gene expression as it expands. Lower serum adiponectin levels are strongly correlated with higher VAT. Because adiponectin normally activates AMP-activated protein kinase (AMPK) to enhance glucose uptake and fatty acid oxidation, its reduction impairs these pathways, leading to elevated HOMA-IR and ectopic lipid accumulation.
• Inflammatory signaling: Visceral fat is highly prone to infiltration by proinflammatory M1-like macrophages. This triggers a chronic low-grade inflammatory state characterized by the secretion of cytokines such as TNF-α and IL-6. These cytokines activate inflammatory kinases, including JNK and IKKβ, which phosphorylate Insulin Receptor Substrate-1 (IRS-1) at inhibitory serine residues (e.g., Ser307). This phosphorylation blocks the PI3K-Akt pathway, preventing necessary GLUT4 translocation and glucose uptake.

Neurological drivers of weight gain

The phenotypic changes seen in AA carriers are largely driven by altered appetite regulation rather than metabolic rate. The rs9939609 variant is associated with changed hypothalamic expression of FTO and IRX3, which leads to:

• Enhanced brain responsiveness to food cues.
• Attenuated post-prandial suppression of ghrelin (the "hunger hormone").
• A cumulative effect of increased energy intake and overconsumption.

Bottom line

The FTO rs9939609 A/A genotype is strongly linked to higher BMI and central adiposity, which drives insulin resistance by lowering the insulin-sensitizing hormone adiponectin and inducing a pro-inflammatory cytokine cascade in visceral fat that disrupts cellular insulin signaling.